Table 2.
Treatment Response.a
| Response for treatment | Cohorts | Comparisons between cohorts, P value | |
|---|---|---|---|
| ACT | PCB | ||
| Treatment | Paclitaxel + carboplatin | Paclitaxel + carboplatin + bevacizumab | |
| Women enrolled | 161 | 127 | |
| Complete response | 82 (51) | 69 (54) | .037 |
| Partial response | 45 (28) | 46 (36) | |
| Stable disease | 26 (16) | 11 (9) | |
| Progressive disease | 8 (5) | 1 (1) | |
a Data are presented as frequency (percentage). The Fisher exact test was performed for statistical analysis. A P < .05 was considered significant. Clinical examinations and the computed tomography were used for treatment response evaluation. RECIST version 1.1 was used for treatment response evaluation.